Biochemical laboratory abnormalities
| . | This study (n = 73) . | Kantarjian et al (n = 280)32 . | |
|---|---|---|---|
| All grades, % . | Grade 3, % . | Grade 3/4, % . | |
| Bilirubin (total) | 53 | 16 | 9 |
| ALT (GPT) | 42 | 8 | 4 |
| γ -GT | 36 | 7 | NR |
| AST (GOT) | 29 | 3 | 1 |
| Alkaline phosphatase | 11 | NR | |
| Lipase | 29 | 8* | 14 |
| Amylase | 18 | 4 | NR |
| Hyperglycemia | 12 | 3 | 12 |
| Hypophosphatemia | 10 | 3 | 15 |
| Creatinine | 7 | NR | |
| Hypocalcemia | 5 | NR | |
| . | This study (n = 73) . | Kantarjian et al (n = 280)32 . | |
|---|---|---|---|
| All grades, % . | Grade 3, % . | Grade 3/4, % . | |
| Bilirubin (total) | 53 | 16 | 9 |
| ALT (GPT) | 42 | 8 | 4 |
| γ -GT | 36 | 7 | NR |
| AST (GOT) | 29 | 3 | 1 |
| Alkaline phosphatase | 11 | NR | |
| Lipase | 29 | 8* | 14 |
| Amylase | 18 | 4 | NR |
| Hyperglycemia | 12 | 3 | 12 |
| Hypophosphatemia | 10 | 3 | 15 |
| Creatinine | 7 | NR | |
| Hypocalcemia | 5 | NR | |
The frequency of grade 3 nonhematologic AEs in these 73 early CP patients is compared with the data previously reported in 280 IM-resistant or intolerant patients who were treated with nilotinib in late CP.32
NR indicates not reported.
Percentages: 4% grade 3 and 4% grade 4.